We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-22.38%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$174M
AUM Growth
-$35M
Cap. Flow
+$36.4M
Cap. Flow %
20.95%
Top 10 Hldgs %
76.37%
Holding
28
New
9
Increased
8
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$5.94M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$5.5M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$4.95M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$3.55M
5
AMRN
Amarin Corp
AMRN
+$3.24M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$920K
2
BLU
BELLUS Health Inc.
BLU
+$842K

Sector Composition

Rank Sector Weight
1 Healthcare 97.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$1.06M 0.61%
+50,000
New +$1.07M
AMRN
27
Amarin Corp
AMRN
$303M
$781K 0.45%
+9,760
New +$3.24M
KALA icon
28
KALA BIO
KALA
$14.5M
$563K 0.32%
+26
New +$415K
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q1 2020 Portfolio in Review

As of Q1 2020, Samsara BioCapital held 28 positions worth $174M, down 17% from $209M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Samsara BioCapital deployed $36.4M of net new capital in Q1 2020, opening 9 new positions and adding to 8 existing holdings. Its largest new stake was Aimmune Therapeutics: 232,571 shares worth $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $920K trimmed.

  • Samsara BioCapital's largest Q1 2020 buy was Aimmune Therapeutics: 232,571 shares worth $3.35M.
  • Samsara BioCapital added most to Principia Biopharma Inc. Common Stock in Q1 2020, an estimated $5.5M increase.
  • Samsara BioCapital's biggest Q1 2020 reduction was SpringWorks Therapeutics, cutting an estimated $920K.
  • Samsara BioCapital's ten largest holdings make up 76% of its $174M portfolio in Q1 2020.
  • Samsara BioCapital opened 9 new positions and closed 0 in Q1 2020.
  • Samsara BioCapital's portfolio value fell 17% quarter-over-quarter to $174M.

Based on Samsara BioCapital's 13F filing for Q1 2020, filed 15 May 2020.